This paper is in the following e-collection/theme issue:

Design and Usability of Clinical Software and EHRs (271) Human Factors and Usability Case Studies (809) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (159) User-centred Design Case Studies (602) Pharmacovigilance (138) Cancer and Clinical Trials (20) Design and Usability of Websites for Special User Groups (171) Patient-Reported Outcome Measures (PROMs) (294)

Published on in Vol 5, No 3 (2018): Jul-Sept

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/10070, first published .
Software for Administering the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study

Software for Administering the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study

Software for Administering the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study

Authors of this article:

Martin W Schoen1 Author Orcid Image ;   Ethan Basch2, 3, 4, 5 Author Orcid Image ;   Lori L Hudson6 Author Orcid Image ;   Arlene E Chung4, 7, 8 Author Orcid Image ;   Tito R Mendoza9 Author Orcid Image ;   Sandra A Mitchell10 Author Orcid Image ;   Diane St. Germain11 Author Orcid Image ;   Paul Baumgartner12 Author Orcid Image ;   Laura Sit3 Author Orcid Image ;   Lauren J Rogak3 Author Orcid Image ;   Marwan Shouery3 Author Orcid Image ;   Eve Shalley13 Author Orcid Image ;   Bryce B Reeve14 Author Orcid Image ;   Maria R Fawzy15 Author Orcid Image ;   Nrupen A Bhavsar16 Author Orcid Image ;   Charles Cleeland9 Author Orcid Image ;   Deborah Schrag17 Author Orcid Image ;   Amylou C Dueck18 Author Orcid Image ;   Amy P Abernethy6, 14, 19 Author Orcid Image
Article Authors Cited by (19) Tweetations (5) Metrics

Journals

  1. Ngai L, ter Veer E, van den Boorn H, van Herk E, van Kleef J, van Oijen M, van Laarhoven H. TOXview: a novel graphical presentation of cancer treatment toxicity profiles. Acta Oncologica 2019;58(8):1138 View
  2. Li L, Kong F, Zhang L, Li X, Fu X, Wang X, Wu J, Zhang F, Ren L, Zhang M. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. Investigational New Drugs 2020;38(6):1847 View
  3. Lazarewicz M, Wlodarczyk D, Lundgren S, Reidunsdatter R. Diversity in changes of HRQoL over a 1-year period after radiotherapy in Norwegian breast cancer patients: results of cluster analyses. Quality of Life Research 2019;28(6):1521 View
  4. Cheng M, Lee H, Chang W, Lee N, Huang H, Chen Y, Horng H, Lee W, Wang P. Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. International Journal of Environmental Research and Public Health 2019;16(23):4794 View
  5. Xiao Y, Zeng L, Shen Q, Zhou Z, Mao Z, Wang Q, Zhang X, Li Y, Yao W. Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors. Journal of Immunology Research 2020;2020:1 View
  6. Huang C, Cheng M, Lee N, Huang H, Lee W, Chang W, Wang P. Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer. International Journal of Environmental Research and Public Health 2020;17(7):2213 View
  7. Basch E, Stover A, Schrag D, Chung A, Jansen J, Henson S, Carr P, Ginos B, Deal A, Spears P, Jonsson M, Bennett A, Mody G, Thanarajasingam G, Rogak L, Reeve B, Snyder C, Kottschade L, Charlot M, Weiss A, Bruner D, Dueck A. Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. JCO Clinical Cancer Informatics 2020;(4):947 View
  8. Fabi A, Terrenato I, Vidiri A, Villani V, Tanzilli A, Airoldi M, Pedani F, Magri V, Palleschi M, Donadio M, Catania G, Nisticò C, Carapella C, Rudà R, Pace A, Maschio M, Telera S, Cognetti F. Eribulin in Brain Metastases of Breast Cancer: Outcomes of the EBRAIM Prospective Observational Trial. Future Oncology 2021;17(26):3445 View
  9. Lee M, Kang D, Kim S, Lim J, Yoon J, Kim Y, Shim S, Kang E, Ahn J, Cho J, Shin S, Oh D. Who is more likely to adopt and comply with the electronic patient-reported outcome measure (ePROM) mobile application? A real-world study with cancer patients undergoing active treatment. Supportive Care in Cancer 2022;30(1):659 View
  10. Mou D, Sisodia R, Castillo-Angeles M, Ladin K, Bergmark R, Pusic A, del Carmen M, Heng M. The Surgeon's Perceived Value of Patient-reported Outcome Measures (PROMs). Annals of Surgery 2022;275(3):500 View
  11. Underwood J, McCloskey S, Raldow A, Kishan A, Zalkin C, Navarro D, Holt L, Webb A, Lynch K, Atkinson T. Developing a Mobile Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Administration System to Capture Postradiation Toxicity in Oncology: Usability and Feasibility Study. JMIR Formative Research 2022;6(4):e27775 View
  12. Patel V, Cunning J, Rios-Diaz A, Mauch J, Nathan S, Messa C, Whitely C, Kozak G, Broach R, Fischer J. Prospective Assessment of the Abdominal Hernia-Q (AHQ)—Patient Burden, Reliability, and Longitudinal Assessment of Quality of Life in Hernia Repair. Annals of Surgery 2022;276(6):1039 View
  13. Basch E, Schrag D, Henson S, Jansen J, Ginos B, Stover A, Carr P, Spears P, Jonsson M, Deal A, Bennett A, Thanarajasingam G, Rogak L, Reeve B, Snyder C, Bruner D, Cella D, Kottschade L, Perlmutter J, Geoghegan C, Samuel-Ryals C, Given B, Mazza G, Miller R, Strasser J, Zylla D, Weiss A, Blinder V, Dueck A. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer. JAMA 2022;327(24):2413 View
  14. Muylle K, Van Laere S, Gentens K, Dupont A, Grosber M, Cornu P. Usability of Graphical User Interfaces With Semiautomatic Delabeling Feature to Improve Drug Allergy Documentation. The Journal of Allergy and Clinical Immunology: In Practice 2023;11(2):519 View
  15. Lehmann J, de Ligt K, Tipelius S, Giesinger J, Sztankay M, Voigt S, van de Poll-Franse L, Rumpold G, Weger R, Willenbacher E, Willenbacher W, Holzner B. Adherence to Patient-Reported Symptom Monitoring and Subsequent Clinical Interventions for Patients With Multiple Myeloma in Outpatient Care: Longitudinal Observational Study. Journal of Medical Internet Research 2023;25:e46017 View
  16. Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano M, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, Criscitiello C, Raffaele M, Beano A, Franco A, Valerio M, Verderame F, Fontana A, Haspinger E, Caldara A, Di Leone A, Tortora G, Giannarelli D, Scambia G. Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. npj Breast Cancer 2023;9(1) View
  17. Blinder V, Deal A, Ginos B, Jansen J, Dueck A, Mazza G, Henson S, Carr P, Rogak L, Weiss A, Rapperport A, Jonsson M, Spears P, Cella D, Gany F, Schrag D, Basch E. Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39). Journal of Clinical Oncology 2023;41(29):4652 View
  18. Ostrovskyi V, Skrypnyk I, Maslova G, Shaposhnyk O, Yakymyshyna L. PECULIARITIES OF MYOCARDIAL BIOELECTRIC ACTIVITY IN PATIENTS WITH PROGRESSIVE MYLTIPLE MYELOMA RECEIVING BORTEZOMIB-CONTAINING CHEMOTHERAPY SCHEMES. Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії 2022;22(3-4):80 View
  19. Drabovska I, Maslova G. IDENTIFYING RISK FACTORS FOR TREATMENT FAILURE IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING BENDAMUSTINE±RITUXIMAB THERAPY. Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії 2024;24(2):18 View